Cannabis

Property	Information
Drug Name	Cannabis and Cannabis-derived Products (e.g., Sativex)
FDA Approval	Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment
Used for	Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects
Clinical Trial Phase	Phase 2 trial for glioblastoma with Sativex combined with temozolomide
Clinical Trial Explanation	Not specified
Common Side Effects	Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products.
OS without	Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months)
OS with	Sativex combined with dose-intense temozolomide: Median survival exceeded 550 days (over 18 months)
PFS without	Not specified
PFS with	Not specifically mentioned; research primarily focused on overall survival and symptomatic relief
Usefulness Rating	4
Usefulness Explanation	Not specified
Toxicity Level	Not specified
Toxicity Explanation	Not specified

Notes: In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.

From Ben Williams Book: Not specified

Loading comments...